Fumaric Acid

Fumaric Acid

SCHEMBL746341

CN1[C@@H]2CC[C@H]1C[C@@H](Nc1ccc(-c3ccc4[nH]ccc4c3)cc1)C2.O=C(O)/C=C/C(=O)O

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol

The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNH2 known ✓ Q12809 2/20 0.38
PTGS2 P35354 1/20 0.45
HDAC2 Q92769 1/20 0.43
GSK3B P49841 2/20 0.40
GSK3A P49840 1/20 0.40
DYRK1A Q13627 1/20 0.40
EPHX1 P07099 1/20 0.40
NPC1 O15118 1/20 0.40
ABL1 P00519 1/20 0.39
CCNC P24863 1/20 0.39
CDK8 P49336 1/20 0.39
FASN P49327 1/20 0.39
KDM4E B2RXH2 1/20 0.39
PIP4K2A P48426 1/20 0.39
PIP4K2B P78356 1/20 0.39
CHRNA7 P36544 2/20 0.38
HDAC1 Q13547 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fumaric Acid SCHEMBL746342 1.00 PTGS2 (0.45) PTGS2HDAC2GSK3BGSK3ADYRK1A
Fumaric Acid SCHEMBL745025 0.91 PTGS2 (0.40) PTGS2HDAC2GSK3BGSK3ANPC1
Fumaric Acid SCHEMBL745026 0.91 PTGS2 (0.40) PTGS2HDAC2GSK3BGSK3ANPC1
SCHEMBL748442 0.91 NPC1 (0.44) PTGS2GSK3BGSK3ADYRK1AEPHX1
SCHEMBL748443 0.91 NPC1 (0.44) PTGS2GSK3BGSK3ADYRK1AEPHX1
Fumaric Acid SCHEMBL989060 0.85 ROCK2 (0.52) GSK3BDYRK1A
Fumaric Acid SCHEMBL989059 0.85 ROCK2 (0.52) GSK3BDYRK1A
SCHEMBL744577 0.81 NPC1 (0.45) PTGS2NPC1ABL1CHRNA7KCNH2
SCHEMBL744578 0.81 NPC1 (0.45) PTGS2NPC1ABL1CHRNA7KCNH2
Fumaric Acid SCHEMBL748370 0.81 CCNC (0.43) NPC1CCNCCDK8FASNKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2431368-B1 CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives ABBVIE BAHAMAS LTD (BS) 2014-08-27 EP disclosed
EP-2431368-A1 CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives Abbott Laboratories (US) 2012-03-21 EP disclosed
EP-2018380-B1 Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives ABBOTT LAB (US) 2011-10-19 EP disclosed
US-7872017-B2 Fused bicycloheterocycle substituted azabicyclic alkane derivatives ABBOTT LABORATORIES (US) 2011-01-18 US disclosed
US-20100305089-A1 Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives ABBOTT LABORATORIES (US) 2010-12-02 US disclosed
US-20080045539-A1 FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES ABBVIE INC. 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045539-A1 FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES MALT1, BMP2, ALKBH2 KCNH2 708/4885PTGS2 1075/4885HDAC2 263/4885
US-20100305089-A1 Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives MALT1, BMP2, ALKBH2 KCNH2 708/4885PTGS2 1075/4885HDAC2 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.